Repros Therapeutics (RPRX) Earning Somewhat Favorable News Coverage, Analysis Finds
News coverage about Repros Therapeutics (NASDAQ:RPRX) has been trending somewhat positive recently, according to AlphaOne. AlphaOne, a unit of Accern, identifies positive and negative media coverage by analyzing more than twenty million blog and news sources. AlphaOne ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Repros Therapeutics earned a media sentiment score of 0.12 on AlphaOne’s scale. AlphaOne also assigned press coverage about the biotechnology company an impact score of 95 out of 100, meaning that recent media coverage is extremely likely to have an effect on the company’s share price in the immediate future.
Here are some of the media headlines that may have impacted Alpha One’s analysis:
- Repros Therapeutics Inc (RPRX) and Professional Diversity Network Inc (IPDN) Shares Needle Moving On Volume – Concord Register (concordregister.com)
- Delving into Shares of Repros Therapeutics Inc. (NasdaqCM:RPRX): A Look at the Numbers – Geneva Journal (genevajournal.com)
- Pre-Bell Stock Alert on EnteroMedics Inc. (NASDAQ:ETRM) and Repros Therapeutics Inc. (NASDAQ:RPRX) – Lenox Ledger (lenoxledger.com)
- Market Review: Indicator Watch for Repros Therapeutics Inc (RPRX) – The Business Union (earlebusinessunion.com)
- REPROS THERAPEUTICS INC. : Other Events, Financial Statements and Exhibits (form 8-K) (4-traders.com)
Shares of Repros Therapeutics (NASDAQ:RPRX) opened at 0.54 on Friday. Repros Therapeutics has a 1-year low of $0.51 and a 1-year high of $2.48. The stock’s 50 day moving average is $0.91 and its 200-day moving average is $1.27. The stock’s market cap is $14.41 million.
Repros Therapeutics (NASDAQ:RPRX) last announced its earnings results on Tuesday, May 9th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by $0.08. The company had revenue of $0.01 million for the quarter. Repros Therapeutics had a negative return on equity of 151.63% and a negative net margin of 39,128.00%. On average, analysts anticipate that Repros Therapeutics will post ($0.76) EPS for the current year.
Separately, S&P Equity Research raised their price target on shares of Repros Therapeutics from $1.22 to $1.50 in a report on Monday, January 30th.
About Repros Therapeutics
Repros Therapeutics, Inc is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis.
Receive News & Stock Ratings for Repros Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repros Therapeutics Inc and related stocks with our FREE daily email newsletter.